nodes	percent_of_prediction	percent_of_DWPC	metapath
Acamprosate—GRM5—head—thyroid cancer	0.00646	0.119	CbGeAlD
Acamprosate—GRIN2C—thyroid gland—thyroid cancer	0.00555	0.102	CbGeAlD
Acamprosate—SLC36A1—Amino acid and oligopeptide SLC transporters—SLC5A5—thyroid cancer	0.00538	0.0305	CbGpPWpGaD
Acamprosate—GRIN2C—head—thyroid cancer	0.00493	0.0907	CbGeAlD
Acamprosate—GRIN2D—head—thyroid cancer	0.00458	0.0843	CbGeAlD
Acamprosate—GRIN3A—head—thyroid cancer	0.00431	0.0793	CbGeAlD
Acamprosate—GRIN1—head—thyroid cancer	0.00408	0.0751	CbGeAlD
Acamprosate—GRIN2B—head—thyroid cancer	0.00389	0.0717	CbGeAlD
Acamprosate—SLC36A1—thyroid gland—thyroid cancer	0.00381	0.0702	CbGeAlD
Acamprosate—GRIN2C—CREB phosphorylation through the activation of Ras—BRAF—thyroid cancer	0.00357	0.0202	CbGpPWpGaD
Acamprosate—GRM5—GPCR ligand binding—CALCB—thyroid cancer	0.00354	0.0201	CbGpPWpGaD
Acamprosate—GRIN2A—head—thyroid cancer	0.0034	0.0627	CbGeAlD
Acamprosate—SLC36A1—head—thyroid cancer	0.00338	0.0623	CbGeAlD
Acamprosate—GRIN2D—CREB phosphorylation through the activation of Ras—BRAF—thyroid cancer	0.00332	0.0188	CbGpPWpGaD
Acamprosate—GRIN1—Mecp2 and Associated Rett Syndrome—SST—thyroid cancer	0.0032	0.0181	CbGpPWpGaD
Acamprosate—SLC36A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC5A5—thyroid cancer	0.00317	0.018	CbGpPWpGaD
Acamprosate—GRIN2C—Post NMDA receptor activation events—BRAF—thyroid cancer	0.00294	0.0166	CbGpPWpGaD
Acamprosate—GRIN2B—ErbB4 signaling events—NRG1—thyroid cancer	0.0028	0.0159	CbGpPWpGaD
Acamprosate—GRIN2D—Post NMDA receptor activation events—BRAF—thyroid cancer	0.00273	0.0155	CbGpPWpGaD
Acamprosate—GRIN2A—CREB phosphorylation through the activation of Ras—BRAF—thyroid cancer	0.00273	0.0154	CbGpPWpGaD
Acamprosate—GRIN2C—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—thyroid cancer	0.00271	0.0153	CbGpPWpGaD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—RET—thyroid cancer	0.00255	0.0144	CbGpPWpGaD
Acamprosate—GRIN2D—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—thyroid cancer	0.00252	0.0143	CbGpPWpGaD
Acamprosate—GRIN1—CREB phosphorylation through the activation of Ras—BRAF—thyroid cancer	0.00238	0.0135	CbGpPWpGaD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—THRB—thyroid cancer	0.00237	0.0134	CbGpPWpGaD
Acamprosate—SLC36A1—lymph node—thyroid cancer	0.00237	0.0436	CbGeAlD
Acamprosate—GRIN2B—CREB phosphorylation through the activation of Ras—BRAF—thyroid cancer	0.00232	0.0131	CbGpPWpGaD
Acamprosate—GRIN2C—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—thyroid cancer	0.0023	0.013	CbGpPWpGaD
Acamprosate—GRIN2A—Post NMDA receptor activation events—BRAF—thyroid cancer	0.00224	0.0127	CbGpPWpGaD
Acamprosate—GABRG2—head—thyroid cancer	0.00214	0.0395	CbGeAlD
Acamprosate—GRIN2D—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—thyroid cancer	0.00214	0.0121	CbGpPWpGaD
Acamprosate—GRIN2A—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—thyroid cancer	0.00207	0.0117	CbGpPWpGaD
Acamprosate—GRM5—GPCR downstream signaling—CALCB—thyroid cancer	0.002	0.0113	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—LGALS3—thyroid cancer	0.00198	0.0112	CbGpPWpGaD
Acamprosate—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—CDK1—thyroid cancer	0.00197	0.0112	CbGpPWpGaD
Acamprosate—GRIN1—Post NMDA receptor activation events—BRAF—thyroid cancer	0.00196	0.0111	CbGpPWpGaD
Acamprosate—GRIN2B—Post NMDA receptor activation events—BRAF—thyroid cancer	0.00191	0.0108	CbGpPWpGaD
Acamprosate—GABRA1—head—thyroid cancer	0.00189	0.0349	CbGeAlD
Acamprosate—SLC36A1—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.00189	0.0107	CbGpPWpGaD
Acamprosate—SLC36A1—SLC-mediated transmembrane transport—CP—thyroid cancer	0.00189	0.0107	CbGpPWpGaD
Acamprosate—GABRB3—thyroid gland—thyroid cancer	0.00186	0.0342	CbGeAlD
Acamprosate—GRM5—Signaling by GPCR—CALCB—thyroid cancer	0.00182	0.0103	CbGpPWpGaD
Acamprosate—GRIN1—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—thyroid cancer	0.0018	0.0102	CbGpPWpGaD
Acamprosate—GRIN2A—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—thyroid cancer	0.00176	0.00996	CbGpPWpGaD
Acamprosate—GRIN2B—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—thyroid cancer	0.00176	0.00995	CbGpPWpGaD
Acamprosate—GABRB3—head—thyroid cancer	0.00165	0.0303	CbGeAlD
Acamprosate—GRIN2C—CREB phosphorylation through the activation of Ras—HRAS—thyroid cancer	0.00164	0.0093	CbGpPWpGaD
Acamprosate—GRM5—GPCR ligand binding—TSHR—thyroid cancer	0.00164	0.00928	CbGpPWpGaD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—PRKAR1A—thyroid cancer	0.00157	0.00892	CbGpPWpGaD
Acamprosate—GRIN1—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—thyroid cancer	0.00153	0.00869	CbGpPWpGaD
Acamprosate—GRIN2D—CREB phosphorylation through the activation of Ras—HRAS—thyroid cancer	0.00153	0.00865	CbGpPWpGaD
Acamprosate—GRIN2B—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—thyroid cancer	0.00149	0.00847	CbGpPWpGaD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—RET—thyroid cancer	0.00144	0.00817	CbGpPWpGaD
Acamprosate—SLC36A1—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.00142	0.00802	CbGpPWpGaD
Acamprosate—GRM5—GPCR ligand binding—PTCH1—thyroid cancer	0.00139	0.00789	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—CDK1—thyroid cancer	0.00136	0.00768	CbGpPWpGaD
Acamprosate—Blood alkaline phosphatase increased—Epirubicin—thyroid cancer	0.00135	0.00176	CcSEcCtD
Acamprosate—Diabetes mellitus—Epirubicin—thyroid cancer	0.00135	0.00176	CcSEcCtD
Acamprosate—GRIN2C—Post NMDA receptor activation events—HRAS—thyroid cancer	0.00135	0.00765	CbGpPWpGaD
Acamprosate—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00135	0.00176	CcSEcCtD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—THRB—thyroid cancer	0.00134	0.0076	CbGpPWpGaD
Acamprosate—Constipation—Sorafenib—thyroid cancer	0.00134	0.00174	CcSEcCtD
Acamprosate—Pain—Sorafenib—thyroid cancer	0.00134	0.00174	CcSEcCtD
Acamprosate—Eczema—Epirubicin—thyroid cancer	0.00131	0.0017	CcSEcCtD
Acamprosate—Abnormal vision—Doxorubicin—thyroid cancer	0.00131	0.0017	CcSEcCtD
Acamprosate—Mental disability—Doxorubicin—thyroid cancer	0.0013	0.00169	CcSEcCtD
Acamprosate—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00128	0.00166	CcSEcCtD
Acamprosate—Lymphadenopathy—Doxorubicin—thyroid cancer	0.00128	0.00166	CcSEcCtD
Acamprosate—GRM5—GPCR ligand binding—SST—thyroid cancer	0.00127	0.00722	CbGpPWpGaD
Acamprosate—Renal failure acute—Epirubicin—thyroid cancer	0.00127	0.00166	CcSEcCtD
Acamprosate—Phlebitis—Doxorubicin—thyroid cancer	0.00126	0.00164	CcSEcCtD
Acamprosate—Thrombophlebitis—Doxorubicin—thyroid cancer	0.00126	0.00164	CcSEcCtD
Acamprosate—GRIN2D—Post NMDA receptor activation events—HRAS—thyroid cancer	0.00126	0.00712	CbGpPWpGaD
Acamprosate—GRIN2A—CREB phosphorylation through the activation of Ras—HRAS—thyroid cancer	0.00125	0.0071	CbGpPWpGaD
Acamprosate—Increased appetite—Epirubicin—thyroid cancer	0.00125	0.00163	CcSEcCtD
Acamprosate—Diabetes mellitus—Doxorubicin—thyroid cancer	0.00125	0.00163	CcSEcCtD
Acamprosate—Blood alkaline phosphatase increased—Doxorubicin—thyroid cancer	0.00125	0.00163	CcSEcCtD
Acamprosate—Dermatitis exfoliative—Epirubicin—thyroid cancer	0.00125	0.00162	CcSEcCtD
Acamprosate—GRIN2C—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—thyroid cancer	0.00124	0.00705	CbGpPWpGaD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—SST—thyroid cancer	0.00124	0.00705	CbGpPWpGaD
Acamprosate—Urticaria—Sorafenib—thyroid cancer	0.00124	0.00162	CcSEcCtD
Acamprosate—Abdominal pain—Sorafenib—thyroid cancer	0.00124	0.00161	CcSEcCtD
Acamprosate—Body temperature increased—Sorafenib—thyroid cancer	0.00124	0.00161	CcSEcCtD
Acamprosate—Dermatitis bullous—Epirubicin—thyroid cancer	0.00123	0.0016	CcSEcCtD
Acamprosate—GRM5—GPCR ligand binding—CALCA—thyroid cancer	0.00123	0.00695	CbGpPWpGaD
Acamprosate—Eczema—Doxorubicin—thyroid cancer	0.00121	0.00158	CcSEcCtD
Acamprosate—Cardiac failure—Epirubicin—thyroid cancer	0.00121	0.00157	CcSEcCtD
Acamprosate—Hyponatraemia—Epirubicin—thyroid cancer	0.00118	0.00154	CcSEcCtD
Acamprosate—Renal failure acute—Doxorubicin—thyroid cancer	0.00118	0.00153	CcSEcCtD
Acamprosate—Gastrointestinal haemorrhage—Epirubicin—thyroid cancer	0.00118	0.00153	CcSEcCtD
Acamprosate—Diplopia—Epirubicin—thyroid cancer	0.00118	0.00153	CcSEcCtD
Acamprosate—Increased appetite—Doxorubicin—thyroid cancer	0.00116	0.00151	CcSEcCtD
Acamprosate—Migraine—Epirubicin—thyroid cancer	0.00116	0.00151	CcSEcCtD
Acamprosate—GRIN2D—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—thyroid cancer	0.00116	0.00655	CbGpPWpGaD
Acamprosate—Dermatitis exfoliative—Doxorubicin—thyroid cancer	0.00115	0.0015	CcSEcCtD
Acamprosate—Hypersensitivity—Sorafenib—thyroid cancer	0.00115	0.0015	CcSEcCtD
Acamprosate—Dermatitis bullous—Doxorubicin—thyroid cancer	0.00114	0.00148	CcSEcCtD
Acamprosate—GRIN2A—Reelin signaling pathway—AKT1—thyroid cancer	0.00114	0.00645	CbGpPWpGaD
Acamprosate—Face oedema—Epirubicin—thyroid cancer	0.00114	0.00148	CcSEcCtD
Acamprosate—Asthenia—Sorafenib—thyroid cancer	0.00112	0.00146	CcSEcCtD
Acamprosate—Cardiac failure—Doxorubicin—thyroid cancer	0.00112	0.00145	CcSEcCtD
Acamprosate—Pruritus—Sorafenib—thyroid cancer	0.00111	0.00144	CcSEcCtD
Acamprosate—Blood creatinine increased—Epirubicin—thyroid cancer	0.0011	0.00143	CcSEcCtD
Acamprosate—GRIN1—CREB phosphorylation through the activation of Ras—HRAS—thyroid cancer	0.00109	0.00619	CbGpPWpGaD
Acamprosate—Hyponatraemia—Doxorubicin—thyroid cancer	0.00109	0.00142	CcSEcCtD
Acamprosate—Gastrointestinal haemorrhage—Doxorubicin—thyroid cancer	0.00109	0.00142	CcSEcCtD
Acamprosate—Diplopia—Doxorubicin—thyroid cancer	0.00109	0.00142	CcSEcCtD
Acamprosate—Liver function test abnormal—Epirubicin—thyroid cancer	0.00109	0.00141	CcSEcCtD
Acamprosate—Dry skin—Epirubicin—thyroid cancer	0.00108	0.0014	CcSEcCtD
Acamprosate—Orthostatic hypotension—Epirubicin—thyroid cancer	0.00107	0.0014	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—CALCB—thyroid cancer	0.00107	0.00608	CbGpPWpGaD
Acamprosate—Migraine—Doxorubicin—thyroid cancer	0.00107	0.00139	CcSEcCtD
Acamprosate—Diarrhoea—Sorafenib—thyroid cancer	0.00107	0.00139	CcSEcCtD
Acamprosate—GRIN2B—CREB phosphorylation through the activation of Ras—HRAS—thyroid cancer	0.00107	0.00604	CbGpPWpGaD
Acamprosate—Breast disorder—Epirubicin—thyroid cancer	0.00106	0.00138	CcSEcCtD
Acamprosate—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	0.00106	0.00138	CcSEcCtD
Acamprosate—Face oedema—Doxorubicin—thyroid cancer	0.00105	0.00137	CcSEcCtD
Acamprosate—Gastritis—Epirubicin—thyroid cancer	0.00104	0.00135	CcSEcCtD
Acamprosate—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.00104	0.00135	CcSEcCtD
Acamprosate—Dizziness—Sorafenib—thyroid cancer	0.00103	0.00135	CcSEcCtD
Acamprosate—GRIN2A—Post NMDA receptor activation events—HRAS—thyroid cancer	0.00103	0.00584	CbGpPWpGaD
Acamprosate—Abdominal distension—Epirubicin—thyroid cancer	0.00102	0.00133	CcSEcCtD
Acamprosate—Blood creatinine increased—Doxorubicin—thyroid cancer	0.00102	0.00133	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—TRIM33—thyroid cancer	0.00102	0.00576	CbGpPWpGaD
Acamprosate—Influenza—Epirubicin—thyroid cancer	0.00102	0.00132	CcSEcCtD
Acamprosate—Dysphagia—Epirubicin—thyroid cancer	0.00102	0.00132	CcSEcCtD
Acamprosate—Asthma—Epirubicin—thyroid cancer	0.00102	0.00132	CcSEcCtD
Acamprosate—GRIN2C—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—thyroid cancer	0.00101	0.00574	CbGpPWpGaD
Acamprosate—Eosinophilia—Epirubicin—thyroid cancer	0.00101	0.00131	CcSEcCtD
Acamprosate—Liver function test abnormal—Doxorubicin—thyroid cancer	0.00101	0.00131	CcSEcCtD
Acamprosate—Dry skin—Doxorubicin—thyroid cancer	0.000998	0.0013	CcSEcCtD
Acamprosate—Pancreatitis—Epirubicin—thyroid cancer	0.000997	0.0013	CcSEcCtD
Acamprosate—Vomiting—Sorafenib—thyroid cancer	0.000995	0.00129	CcSEcCtD
Acamprosate—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.000994	0.00129	CcSEcCtD
Acamprosate—Angina pectoris—Epirubicin—thyroid cancer	0.000991	0.00129	CcSEcCtD
Acamprosate—Rash—Sorafenib—thyroid cancer	0.000987	0.00128	CcSEcCtD
Acamprosate—Dermatitis—Sorafenib—thyroid cancer	0.000986	0.00128	CcSEcCtD
Acamprosate—Breast disorder—Doxorubicin—thyroid cancer	0.000984	0.00128	CcSEcCtD
Acamprosate—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.00098	0.00127	CcSEcCtD
Acamprosate—Headache—Sorafenib—thyroid cancer	0.00098	0.00127	CcSEcCtD
Acamprosate—Bronchitis—Epirubicin—thyroid cancer	0.000978	0.00127	CcSEcCtD
Acamprosate—GRIN2B—Reelin signaling pathway—AKT1—thyroid cancer	0.000968	0.00548	CbGpPWpGaD
Acamprosate—Gastritis—Doxorubicin—thyroid cancer	0.000964	0.00125	CcSEcCtD
Acamprosate—SLC36A1—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000961	0.00545	CbGpPWpGaD
Acamprosate—SLC36A1—Transmembrane transport of small molecules—CP—thyroid cancer	0.000961	0.00545	CbGpPWpGaD
Acamprosate—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.00096	0.00125	CcSEcCtD
Acamprosate—GRIN2A—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—thyroid cancer	0.00095	0.00538	CbGpPWpGaD
Acamprosate—Abdominal distension—Doxorubicin—thyroid cancer	0.000947	0.00123	CcSEcCtD
Acamprosate—SLC36A1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000946	0.00536	CbGpPWpGaD
Acamprosate—GRIN2D—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—thyroid cancer	0.000942	0.00534	CbGpPWpGaD
Acamprosate—Influenza—Doxorubicin—thyroid cancer	0.000941	0.00122	CcSEcCtD
Acamprosate—Asthma—Doxorubicin—thyroid cancer	0.000941	0.00122	CcSEcCtD
Acamprosate—Dysphagia—Doxorubicin—thyroid cancer	0.000941	0.00122	CcSEcCtD
Acamprosate—Pollakiuria—Epirubicin—thyroid cancer	0.000939	0.00122	CcSEcCtD
Acamprosate—Eosinophilia—Doxorubicin—thyroid cancer	0.000932	0.00121	CcSEcCtD
Acamprosate—Nausea—Sorafenib—thyroid cancer	0.000929	0.00121	CcSEcCtD
Acamprosate—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000928	0.00121	CcSEcCtD
Acamprosate—GRM5—GPCR downstream signaling—TSHR—thyroid cancer	0.000926	0.00525	CbGpPWpGaD
Acamprosate—Weight increased—Epirubicin—thyroid cancer	0.000926	0.0012	CcSEcCtD
Acamprosate—Pancreatitis—Doxorubicin—thyroid cancer	0.000923	0.0012	CcSEcCtD
Acamprosate—Weight decreased—Epirubicin—thyroid cancer	0.00092	0.0012	CcSEcCtD
Acamprosate—GABRB3—Orphan transporters—RXRA—thyroid cancer	0.000918	0.0052	CbGpPWpGaD
Acamprosate—Hyperglycaemia—Epirubicin—thyroid cancer	0.000917	0.00119	CcSEcCtD
Acamprosate—Angina pectoris—Doxorubicin—thyroid cancer	0.000917	0.00119	CcSEcCtD
Acamprosate—Pneumonia—Epirubicin—thyroid cancer	0.000912	0.00119	CcSEcCtD
Acamprosate—Bronchitis—Doxorubicin—thyroid cancer	0.000905	0.00118	CcSEcCtD
Acamprosate—GABRG2—Orphan transporters—RXRA—thyroid cancer	0.000902	0.00511	CbGpPWpGaD
Acamprosate—GRIN1—Post NMDA receptor activation events—HRAS—thyroid cancer	0.0009	0.0051	CbGpPWpGaD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—PRKAR1A—thyroid cancer	0.000891	0.00505	CbGpPWpGaD
Acamprosate—Stomatitis—Epirubicin—thyroid cancer	0.000884	0.00115	CcSEcCtD
Acamprosate—Urinary tract infection—Epirubicin—thyroid cancer	0.000881	0.00115	CcSEcCtD
Acamprosate—GRIN2B—Post NMDA receptor activation events—HRAS—thyroid cancer	0.000877	0.00497	CbGpPWpGaD
Acamprosate—Sweating—Epirubicin—thyroid cancer	0.000869	0.00113	CcSEcCtD
Acamprosate—Pollakiuria—Doxorubicin—thyroid cancer	0.000869	0.00113	CcSEcCtD
Acamprosate—Haematuria—Epirubicin—thyroid cancer	0.000865	0.00112	CcSEcCtD
Acamprosate—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.000859	0.00112	CcSEcCtD
Acamprosate—Weight increased—Doxorubicin—thyroid cancer	0.000856	0.00111	CcSEcCtD
Acamprosate—Epistaxis—Epirubicin—thyroid cancer	0.000855	0.00111	CcSEcCtD
Acamprosate—Weight decreased—Doxorubicin—thyroid cancer	0.000851	0.00111	CcSEcCtD
Acamprosate—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000849	0.0011	CcSEcCtD
Acamprosate—Pneumonia—Doxorubicin—thyroid cancer	0.000844	0.0011	CcSEcCtD
Acamprosate—GRM5—Signaling by GPCR—TSHR—thyroid cancer	0.000841	0.00476	CbGpPWpGaD
Acamprosate—GRIN1—EPHB-mediated forward signaling—HRAS—thyroid cancer	0.000829	0.00469	CbGpPWpGaD
Acamprosate—GRIN1—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—thyroid cancer	0.000829	0.00469	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000827	0.00469	CbGpPWpGaD
Acamprosate—Haemoglobin—Epirubicin—thyroid cancer	0.000818	0.00106	CcSEcCtD
Acamprosate—Stomatitis—Doxorubicin—thyroid cancer	0.000818	0.00106	CcSEcCtD
Acamprosate—Rhinitis—Epirubicin—thyroid cancer	0.000816	0.00106	CcSEcCtD
Acamprosate—Urinary tract infection—Doxorubicin—thyroid cancer	0.000816	0.00106	CcSEcCtD
Acamprosate—Haemorrhage—Epirubicin—thyroid cancer	0.000814	0.00106	CcSEcCtD
Acamprosate—Hepatitis—Epirubicin—thyroid cancer	0.000814	0.00106	CcSEcCtD
Acamprosate—Hypoaesthesia—Epirubicin—thyroid cancer	0.00081	0.00105	CcSEcCtD
Acamprosate—GRIN2B—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—thyroid cancer	0.000808	0.00458	CbGpPWpGaD
Acamprosate—GRIN2B—EPHB-mediated forward signaling—HRAS—thyroid cancer	0.000808	0.00458	CbGpPWpGaD
Acamprosate—Pharyngitis—Epirubicin—thyroid cancer	0.000808	0.00105	CcSEcCtD
Acamprosate—Sweating—Doxorubicin—thyroid cancer	0.000804	0.00105	CcSEcCtD
Acamprosate—Oedema peripheral—Epirubicin—thyroid cancer	0.000802	0.00104	CcSEcCtD
Acamprosate—Haematuria—Doxorubicin—thyroid cancer	0.0008	0.00104	CcSEcCtD
Acamprosate—Epistaxis—Doxorubicin—thyroid cancer	0.000791	0.00103	CcSEcCtD
Acamprosate—GABRA1—Orphan transporters—RXRA—thyroid cancer	0.000788	0.00447	CbGpPWpGaD
Acamprosate—Visual impairment—Epirubicin—thyroid cancer	0.000784	0.00102	CcSEcCtD
Acamprosate—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—thyroid cancer	0.000774	0.00438	CbGpPWpGaD
Acamprosate—GRIN2C—Alzheimers Disease—TP53—thyroid cancer	0.00077	0.00436	CbGpPWpGaD
Acamprosate—GRIN2C—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000762	0.00432	CbGpPWpGaD
Acamprosate—Tinnitus—Epirubicin—thyroid cancer	0.000759	0.000987	CcSEcCtD
Acamprosate—Haemoglobin—Doxorubicin—thyroid cancer	0.000757	0.000984	CcSEcCtD
Acamprosate—Rhinitis—Doxorubicin—thyroid cancer	0.000755	0.000982	CcSEcCtD
Acamprosate—Hepatitis—Doxorubicin—thyroid cancer	0.000753	0.000979	CcSEcCtD
Acamprosate—Haemorrhage—Doxorubicin—thyroid cancer	0.000753	0.000979	CcSEcCtD
Acamprosate—Hypoaesthesia—Doxorubicin—thyroid cancer	0.000749	0.000974	CcSEcCtD
Acamprosate—Pharyngitis—Doxorubicin—thyroid cancer	0.000748	0.000972	CcSEcCtD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—HIF1A—thyroid cancer	0.000747	0.00423	CbGpPWpGaD
Acamprosate—Oedema peripheral—Doxorubicin—thyroid cancer	0.000742	0.000965	CcSEcCtD
Acamprosate—Immune system disorder—Epirubicin—thyroid cancer	0.000735	0.000956	CcSEcCtD
Acamprosate—Chills—Epirubicin—thyroid cancer	0.00073	0.00095	CcSEcCtD
Acamprosate—Visual impairment—Doxorubicin—thyroid cancer	0.000726	0.000944	CcSEcCtD
Acamprosate—GRM5—GPCR downstream signaling—SST—thyroid cancer	0.00072	0.00408	CbGpPWpGaD
Acamprosate—SLC36A1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.00072	0.00408	CbGpPWpGaD
Acamprosate—Alopecia—Epirubicin—thyroid cancer	0.000719	0.000935	CcSEcCtD
Acamprosate—GRIN2D—Alzheimers Disease—TP53—thyroid cancer	0.000716	0.00406	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—PTCH1—thyroid cancer	0.000715	0.00405	CbGpPWpGaD
Acamprosate—Mental disorder—Epirubicin—thyroid cancer	0.000713	0.000927	CcSEcCtD
Acamprosate—Malnutrition—Epirubicin—thyroid cancer	0.000709	0.000921	CcSEcCtD
Acamprosate—GRIN2D—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000708	0.00401	CbGpPWpGaD
Acamprosate—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	0.000706	0.004	CbGpPWpGaD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—SST—thyroid cancer	0.000705	0.00399	CbGpPWpGaD
Acamprosate—Tinnitus—Doxorubicin—thyroid cancer	0.000702	0.000913	CcSEcCtD
Acamprosate—Flatulence—Epirubicin—thyroid cancer	0.000698	0.000908	CcSEcCtD
Acamprosate—Tension—Epirubicin—thyroid cancer	0.000695	0.000904	CcSEcCtD
Acamprosate—Dysgeusia—Epirubicin—thyroid cancer	0.000694	0.000902	CcSEcCtD
Acamprosate—GRM5—GPCR downstream signaling—CALCA—thyroid cancer	0.000693	0.00393	CbGpPWpGaD
Acamprosate—Nervousness—Epirubicin—thyroid cancer	0.000688	0.000895	CcSEcCtD
Acamprosate—Back pain—Epirubicin—thyroid cancer	0.000685	0.000891	CcSEcCtD
Acamprosate—Muscle spasms—Epirubicin—thyroid cancer	0.000681	0.000886	CcSEcCtD
Acamprosate—Immune system disorder—Doxorubicin—thyroid cancer	0.00068	0.000884	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—TCF7L1—thyroid cancer	0.000679	0.00385	CbGpPWpGaD
Acamprosate—Chills—Doxorubicin—thyroid cancer	0.000676	0.000879	CcSEcCtD
Acamprosate—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—thyroid cancer	0.000675	0.00382	CbGpPWpGaD
Acamprosate—Alopecia—Doxorubicin—thyroid cancer	0.000666	0.000865	CcSEcCtD
Acamprosate—Mental disorder—Doxorubicin—thyroid cancer	0.00066	0.000858	CcSEcCtD
Acamprosate—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—thyroid cancer	0.000658	0.00373	CbGpPWpGaD
Acamprosate—Ill-defined disorder—Epirubicin—thyroid cancer	0.000657	0.000855	CcSEcCtD
Acamprosate—Malnutrition—Doxorubicin—thyroid cancer	0.000656	0.000852	CcSEcCtD
Acamprosate—Anaemia—Epirubicin—thyroid cancer	0.000655	0.000851	CcSEcCtD
Acamprosate—GRM5—Signaling by GPCR—SST—thyroid cancer	0.000654	0.00371	CbGpPWpGaD
Acamprosate—Agitation—Epirubicin—thyroid cancer	0.000651	0.000847	CcSEcCtD
Acamprosate—Flatulence—Doxorubicin—thyroid cancer	0.000646	0.00084	CcSEcCtD
Acamprosate—Tension—Doxorubicin—thyroid cancer	0.000643	0.000836	CcSEcCtD
Acamprosate—Dysgeusia—Doxorubicin—thyroid cancer	0.000642	0.000835	CcSEcCtD
Acamprosate—Malaise—Epirubicin—thyroid cancer	0.000639	0.000831	CcSEcCtD
Acamprosate—Nervousness—Doxorubicin—thyroid cancer	0.000637	0.000828	CcSEcCtD
Acamprosate—Vertigo—Epirubicin—thyroid cancer	0.000637	0.000828	CcSEcCtD
Acamprosate—Syncope—Epirubicin—thyroid cancer	0.000635	0.000826	CcSEcCtD
Acamprosate—Leukopenia—Epirubicin—thyroid cancer	0.000634	0.000825	CcSEcCtD
Acamprosate—Back pain—Doxorubicin—thyroid cancer	0.000634	0.000825	CcSEcCtD
Acamprosate—Muscle spasms—Doxorubicin—thyroid cancer	0.00063	0.00082	CcSEcCtD
Acamprosate—GRM5—Signaling by GPCR—CALCA—thyroid cancer	0.00063	0.00357	CbGpPWpGaD
Acamprosate—Palpitations—Epirubicin—thyroid cancer	0.000626	0.000814	CcSEcCtD
Acamprosate—GRIN1—Spinal Cord Injury—PTGS2—thyroid cancer	0.000625	0.00354	CbGpPWpGaD
Acamprosate—Loss of consciousness—Epirubicin—thyroid cancer	0.000623	0.00081	CcSEcCtD
Acamprosate—Cough—Epirubicin—thyroid cancer	0.000618	0.000804	CcSEcCtD
Acamprosate—Convulsion—Epirubicin—thyroid cancer	0.000614	0.000798	CcSEcCtD
Acamprosate—Hypertension—Epirubicin—thyroid cancer	0.000612	0.000795	CcSEcCtD
Acamprosate—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000608	0.000791	CcSEcCtD
Acamprosate—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	0.000608	0.00344	CbGpPWpGaD
Acamprosate—Anaemia—Doxorubicin—thyroid cancer	0.000606	0.000788	CcSEcCtD
Acamprosate—SLC36A1—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000605	0.00343	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—CDK1—thyroid cancer	0.000604	0.00342	CbGpPWpGaD
Acamprosate—Arthralgia—Epirubicin—thyroid cancer	0.000603	0.000784	CcSEcCtD
Acamprosate—Myalgia—Epirubicin—thyroid cancer	0.000603	0.000784	CcSEcCtD
Acamprosate—Chest pain—Epirubicin—thyroid cancer	0.000603	0.000784	CcSEcCtD
Acamprosate—Agitation—Doxorubicin—thyroid cancer	0.000603	0.000783	CcSEcCtD
Acamprosate—Anxiety—Epirubicin—thyroid cancer	0.000601	0.000782	CcSEcCtD
Acamprosate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000599	0.000779	CcSEcCtD
Acamprosate—Discomfort—Epirubicin—thyroid cancer	0.000596	0.000775	CcSEcCtD
Acamprosate—Malaise—Doxorubicin—thyroid cancer	0.000591	0.000769	CcSEcCtD
Acamprosate—Dry mouth—Epirubicin—thyroid cancer	0.00059	0.000767	CcSEcCtD
Acamprosate—Vertigo—Doxorubicin—thyroid cancer	0.000589	0.000766	CcSEcCtD
Acamprosate—GRIN2B—Axon guidance—CDK1—thyroid cancer	0.000589	0.00334	CbGpPWpGaD
Acamprosate—Syncope—Doxorubicin—thyroid cancer	0.000588	0.000764	CcSEcCtD
Acamprosate—GRIN2A—Alzheimers Disease—TP53—thyroid cancer	0.000588	0.00333	CbGpPWpGaD
Acamprosate—Leukopenia—Doxorubicin—thyroid cancer	0.000587	0.000763	CcSEcCtD
Acamprosate—GRIN2C—Neuronal System—BRAF—thyroid cancer	0.000584	0.00331	CbGpPWpGaD
Acamprosate—Confusional state—Epirubicin—thyroid cancer	0.000583	0.000758	CcSEcCtD
Acamprosate—GRIN2A—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000582	0.0033	CbGpPWpGaD
Acamprosate—Palpitations—Doxorubicin—thyroid cancer	0.000579	0.000753	CcSEcCtD
Acamprosate—Anaphylactic shock—Epirubicin—thyroid cancer	0.000578	0.000752	CcSEcCtD
Acamprosate—Loss of consciousness—Doxorubicin—thyroid cancer	0.000576	0.000749	CcSEcCtD
Acamprosate—Infection—Epirubicin—thyroid cancer	0.000575	0.000747	CcSEcCtD
Acamprosate—Cough—Doxorubicin—thyroid cancer	0.000572	0.000744	CcSEcCtD
Acamprosate—GRM5—Signaling by GPCR—CDK1—thyroid cancer	0.00057	0.00323	CbGpPWpGaD
Acamprosate—Shock—Epirubicin—thyroid cancer	0.000569	0.00074	CcSEcCtD
Acamprosate—Convulsion—Doxorubicin—thyroid cancer	0.000568	0.000739	CcSEcCtD
Acamprosate—Thrombocytopenia—Epirubicin—thyroid cancer	0.000566	0.000736	CcSEcCtD
Acamprosate—Hypertension—Doxorubicin—thyroid cancer	0.000566	0.000736	CcSEcCtD
Acamprosate—GRIN1—Spinal Cord Injury—CCND1—thyroid cancer	0.000565	0.0032	CbGpPWpGaD
Acamprosate—Tachycardia—Epirubicin—thyroid cancer	0.000564	0.000734	CcSEcCtD
Acamprosate—Skin disorder—Epirubicin—thyroid cancer	0.000562	0.00073	CcSEcCtD
Acamprosate—Hyperhidrosis—Epirubicin—thyroid cancer	0.000559	0.000727	CcSEcCtD
Acamprosate—Myalgia—Doxorubicin—thyroid cancer	0.000558	0.000726	CcSEcCtD
Acamprosate—Arthralgia—Doxorubicin—thyroid cancer	0.000558	0.000726	CcSEcCtD
Acamprosate—Chest pain—Doxorubicin—thyroid cancer	0.000558	0.000726	CcSEcCtD
Acamprosate—Anxiety—Doxorubicin—thyroid cancer	0.000556	0.000723	CcSEcCtD
Acamprosate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000554	0.000721	CcSEcCtD
Acamprosate—Discomfort—Doxorubicin—thyroid cancer	0.000551	0.000717	CcSEcCtD
Acamprosate—Anorexia—Epirubicin—thyroid cancer	0.000551	0.000717	CcSEcCtD
Acamprosate—Dry mouth—Doxorubicin—thyroid cancer	0.000546	0.00071	CcSEcCtD
Acamprosate—GRIN2D—Neuronal System—BRAF—thyroid cancer	0.000543	0.00307	CbGpPWpGaD
Acamprosate—Hypotension—Epirubicin—thyroid cancer	0.00054	0.000703	CcSEcCtD
Acamprosate—Confusional state—Doxorubicin—thyroid cancer	0.00054	0.000701	CcSEcCtD
Acamprosate—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000535	0.000696	CcSEcCtD
Acamprosate—Infection—Doxorubicin—thyroid cancer	0.000532	0.000691	CcSEcCtD
Acamprosate—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000527	0.000685	CcSEcCtD
Acamprosate—Shock—Doxorubicin—thyroid cancer	0.000526	0.000684	CcSEcCtD
Acamprosate—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000524	0.000681	CcSEcCtD
Acamprosate—Insomnia—Epirubicin—thyroid cancer	0.000523	0.00068	CcSEcCtD
Acamprosate—Tachycardia—Doxorubicin—thyroid cancer	0.000522	0.000679	CcSEcCtD
Acamprosate—Skin disorder—Doxorubicin—thyroid cancer	0.00052	0.000676	CcSEcCtD
Acamprosate—Paraesthesia—Epirubicin—thyroid cancer	0.000519	0.000675	CcSEcCtD
Acamprosate—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000517	0.000673	CcSEcCtD
Acamprosate—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	0.000517	0.00293	CbGpPWpGaD
Acamprosate—Dyspnoea—Epirubicin—thyroid cancer	0.000516	0.00067	CcSEcCtD
Acamprosate—Somnolence—Epirubicin—thyroid cancer	0.000514	0.000668	CcSEcCtD
Acamprosate—GRIN1—Alzheimers Disease—TP53—thyroid cancer	0.000513	0.0029	CbGpPWpGaD
Acamprosate—Anorexia—Doxorubicin—thyroid cancer	0.00051	0.000663	CcSEcCtD
Acamprosate—Dyspepsia—Epirubicin—thyroid cancer	0.000509	0.000662	CcSEcCtD
Acamprosate—GRIN1—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000507	0.00287	CbGpPWpGaD
Acamprosate—Decreased appetite—Epirubicin—thyroid cancer	0.000503	0.000654	CcSEcCtD
Acamprosate—Hypotension—Doxorubicin—thyroid cancer	0.0005	0.00065	CcSEcCtD
Acamprosate—GRIN2B—Alzheimers Disease—TP53—thyroid cancer	0.0005	0.00283	CbGpPWpGaD
Acamprosate—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000499	0.000649	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—TSHR—thyroid cancer	0.000497	0.00281	CbGpPWpGaD
Acamprosate—GRIN2B—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000495	0.0028	CbGpPWpGaD
Acamprosate—Constipation—Epirubicin—thyroid cancer	0.000495	0.000643	CcSEcCtD
Acamprosate—Pain—Epirubicin—thyroid cancer	0.000495	0.000643	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—PRKAR1A—thyroid cancer	0.000489	0.00277	CbGpPWpGaD
Acamprosate—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000488	0.000634	CcSEcCtD
Acamprosate—Insomnia—Doxorubicin—thyroid cancer	0.000484	0.000629	CcSEcCtD
Acamprosate—Paraesthesia—Doxorubicin—thyroid cancer	0.00048	0.000625	CcSEcCtD
Acamprosate—Dyspnoea—Doxorubicin—thyroid cancer	0.000477	0.00062	CcSEcCtD
Acamprosate—Feeling abnormal—Epirubicin—thyroid cancer	0.000477	0.00062	CcSEcCtD
Acamprosate—Somnolence—Doxorubicin—thyroid cancer	0.000476	0.000618	CcSEcCtD
Acamprosate—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000473	0.000615	CcSEcCtD
Acamprosate—Dyspepsia—Doxorubicin—thyroid cancer	0.000471	0.000612	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—MEN1—thyroid cancer	0.000467	0.00265	CbGpPWpGaD
Acamprosate—GRIN2C—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	0.000466	0.00264	CbGpPWpGaD
Acamprosate—Decreased appetite—Doxorubicin—thyroid cancer	0.000465	0.000605	CcSEcCtD
Acamprosate—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000462	0.000601	CcSEcCtD
Acamprosate—Urticaria—Epirubicin—thyroid cancer	0.000459	0.000597	CcSEcCtD
Acamprosate—Pain—Doxorubicin—thyroid cancer	0.000458	0.000595	CcSEcCtD
Acamprosate—Constipation—Doxorubicin—thyroid cancer	0.000458	0.000595	CcSEcCtD
Acamprosate—Abdominal pain—Epirubicin—thyroid cancer	0.000457	0.000594	CcSEcCtD
Acamprosate—Body temperature increased—Epirubicin—thyroid cancer	0.000457	0.000594	CcSEcCtD
Acamprosate—GRIN2A—Neuronal System—BRAF—thyroid cancer	0.000446	0.00252	CbGpPWpGaD
Acamprosate—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—thyroid cancer	0.000445	0.00252	CbGpPWpGaD
Acamprosate—Feeling abnormal—Doxorubicin—thyroid cancer	0.000441	0.000573	CcSEcCtD
Acamprosate—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000438	0.000569	CcSEcCtD
Acamprosate—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—thyroid cancer	0.000437	0.00248	CbGpPWpGaD
Acamprosate—GRIN2D—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	0.000433	0.00245	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—CDK1—thyroid cancer	0.000431	0.00244	CbGpPWpGaD
Acamprosate—GRIN1—EPH-Ephrin signaling—HRAS—thyroid cancer	0.000427	0.00242	CbGpPWpGaD
Acamprosate—Hypersensitivity—Epirubicin—thyroid cancer	0.000426	0.000554	CcSEcCtD
Acamprosate—Urticaria—Doxorubicin—thyroid cancer	0.000425	0.000553	CcSEcCtD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—HIF1A—thyroid cancer	0.000423	0.0024	CbGpPWpGaD
Acamprosate—Abdominal pain—Doxorubicin—thyroid cancer	0.000423	0.00055	CcSEcCtD
Acamprosate—Body temperature increased—Doxorubicin—thyroid cancer	0.000423	0.00055	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—PTCH1—thyroid cancer	0.000422	0.00239	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—CDK1—thyroid cancer	0.00042	0.00238	CbGpPWpGaD
Acamprosate—GRIN2B—EPH-Ephrin signaling—HRAS—thyroid cancer	0.000416	0.00236	CbGpPWpGaD
Acamprosate—Asthenia—Epirubicin—thyroid cancer	0.000415	0.000539	CcSEcCtD
Acamprosate—Pruritus—Epirubicin—thyroid cancer	0.000409	0.000532	CcSEcCtD
Acamprosate—GRIN1—Developmental Biology—RXRA—thyroid cancer	0.0004	0.00227	CbGpPWpGaD
Acamprosate—Diarrhoea—Epirubicin—thyroid cancer	0.000396	0.000514	CcSEcCtD
Acamprosate—Hypersensitivity—Doxorubicin—thyroid cancer	0.000394	0.000513	CcSEcCtD
Acamprosate—GRIN2B—Developmental Biology—RXRA—thyroid cancer	0.00039	0.00221	CbGpPWpGaD
Acamprosate—GRIN1—Neuronal System—BRAF—thyroid cancer	0.000389	0.0022	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—SST—thyroid cancer	0.000386	0.00219	CbGpPWpGaD
Acamprosate—Asthenia—Doxorubicin—thyroid cancer	0.000384	0.000499	CcSEcCtD
Acamprosate—Dizziness—Epirubicin—thyroid cancer	0.000382	0.000497	CcSEcCtD
Acamprosate—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—thyroid cancer	0.000382	0.00216	CbGpPWpGaD
Acamprosate—GRIN2B—Neuronal System—BRAF—thyroid cancer	0.000379	0.00215	CbGpPWpGaD
Acamprosate—Pruritus—Doxorubicin—thyroid cancer	0.000379	0.000492	CcSEcCtD
Acamprosate—GRIN1—Spinal Cord Injury—TP53—thyroid cancer	0.000372	0.00211	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—CALCA—thyroid cancer	0.000372	0.00211	CbGpPWpGaD
Acamprosate—Vomiting—Epirubicin—thyroid cancer	0.000368	0.000478	CcSEcCtD
Acamprosate—Diarrhoea—Doxorubicin—thyroid cancer	0.000366	0.000476	CcSEcCtD
Acamprosate—Rash—Epirubicin—thyroid cancer	0.000365	0.000474	CcSEcCtD
Acamprosate—Dermatitis—Epirubicin—thyroid cancer	0.000364	0.000474	CcSEcCtD
Acamprosate—Headache—Epirubicin—thyroid cancer	0.000362	0.000471	CcSEcCtD
Acamprosate—GABRB3—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000356	0.00202	CbGpPWpGaD
Acamprosate—GABRB3—Transmembrane transport of small molecules—CP—thyroid cancer	0.000356	0.00202	CbGpPWpGaD
Acamprosate—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	0.000356	0.00202	CbGpPWpGaD
Acamprosate—Dizziness—Doxorubicin—thyroid cancer	0.000354	0.00046	CcSEcCtD
Acamprosate—GABRB3—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000351	0.00199	CbGpPWpGaD
Acamprosate—GRIN2C—Transmission across Chemical Synapses—HRAS—thyroid cancer	0.00035	0.00198	CbGpPWpGaD
Acamprosate—GABRG2—Transmembrane transport of small molecules—CP—thyroid cancer	0.00035	0.00198	CbGpPWpGaD
Acamprosate—GABRG2—Transmembrane transport of small molecules—TPR—thyroid cancer	0.00035	0.00198	CbGpPWpGaD
Acamprosate—GABRG2—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000344	0.00195	CbGpPWpGaD
Acamprosate—Nausea—Epirubicin—thyroid cancer	0.000344	0.000447	CcSEcCtD
Acamprosate—Vomiting—Doxorubicin—thyroid cancer	0.00034	0.000442	CcSEcCtD
Acamprosate—Rash—Doxorubicin—thyroid cancer	0.000337	0.000439	CcSEcCtD
Acamprosate—Dermatitis—Doxorubicin—thyroid cancer	0.000337	0.000438	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—CDK1—thyroid cancer	0.000337	0.00191	CbGpPWpGaD
Acamprosate—Headache—Doxorubicin—thyroid cancer	0.000335	0.000436	CcSEcCtD
Acamprosate—GABRB3—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000335	0.0019	CbGpPWpGaD
Acamprosate—GABRG2—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000329	0.00186	CbGpPWpGaD
Acamprosate—GRIN2D—Transmission across Chemical Synapses—HRAS—thyroid cancer	0.000326	0.00184	CbGpPWpGaD
Acamprosate—Nausea—Doxorubicin—thyroid cancer	0.000318	0.000413	CcSEcCtD
Acamprosate—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	0.00031	0.00176	CbGpPWpGaD
Acamprosate—GABRA1—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000306	0.00173	CbGpPWpGaD
Acamprosate—GABRA1—Transmembrane transport of small molecules—CP—thyroid cancer	0.000306	0.00173	CbGpPWpGaD
Acamprosate—GRIN1—BDNF signaling pathway—HRAS—thyroid cancer	0.000303	0.00172	CbGpPWpGaD
Acamprosate—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	0.000302	0.00171	CbGpPWpGaD
Acamprosate—GABRA1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000301	0.00171	CbGpPWpGaD
Acamprosate—GRIN2B—BDNF signaling pathway—HRAS—thyroid cancer	0.000296	0.00168	CbGpPWpGaD
Acamprosate—GABRA1—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000287	0.00163	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—NRG1—thyroid cancer	0.00027	0.00153	CbGpPWpGaD
Acamprosate—GRIN2C—Neuronal System—HRAS—thyroid cancer	0.000268	0.00152	CbGpPWpGaD
Acamprosate—GRIN1—BDNF signaling pathway—AKT1—thyroid cancer	0.000268	0.00152	CbGpPWpGaD
Acamprosate—GRIN2A—Transmission across Chemical Synapses—HRAS—thyroid cancer	0.000267	0.00151	CbGpPWpGaD
Acamprosate—GABRB3—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000267	0.00151	CbGpPWpGaD
Acamprosate—GABRG2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000262	0.00148	CbGpPWpGaD
Acamprosate—GRIN2B—BDNF signaling pathway—AKT1—thyroid cancer	0.000261	0.00148	CbGpPWpGaD
Acamprosate—GABRB3—Neuronal System—BRAF—thyroid cancer	0.000256	0.00145	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—PPARG—thyroid cancer	0.000253	0.00143	CbGpPWpGaD
Acamprosate—GABRG2—Neuronal System—BRAF—thyroid cancer	0.000252	0.00143	CbGpPWpGaD
Acamprosate—GRIN2D—Neuronal System—HRAS—thyroid cancer	0.00025	0.00141	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—PPARG—thyroid cancer	0.000246	0.0014	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—TERT—thyroid cancer	0.000243	0.00137	CbGpPWpGaD
Acamprosate—GRIN1—Transmission across Chemical Synapses—HRAS—thyroid cancer	0.000233	0.00132	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—HIF1A—thyroid cancer	0.000232	0.00131	CbGpPWpGaD
Acamprosate—GABRA1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000229	0.0013	CbGpPWpGaD
Acamprosate—GRIN2B—Transmission across Chemical Synapses—HRAS—thyroid cancer	0.000227	0.00129	CbGpPWpGaD
Acamprosate—GABRB3—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000224	0.00127	CbGpPWpGaD
Acamprosate—GABRG2—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.00022	0.00125	CbGpPWpGaD
Acamprosate—GABRA1—Neuronal System—BRAF—thyroid cancer	0.00022	0.00125	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—NRAS—thyroid cancer	0.000217	0.00123	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—NRAS—thyroid cancer	0.000211	0.0012	CbGpPWpGaD
Acamprosate—GRIN2A—Neuronal System—HRAS—thyroid cancer	0.000205	0.00116	CbGpPWpGaD
Acamprosate—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	0.000205	0.00116	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—NRAS—thyroid cancer	0.000204	0.00116	CbGpPWpGaD
Acamprosate—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	0.000201	0.00114	CbGpPWpGaD
Acamprosate—GABRB3—BDNF signaling pathway—HRAS—thyroid cancer	0.0002	0.00113	CbGpPWpGaD
Acamprosate—GABRA1—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000192	0.00109	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—BRAF—thyroid cancer	0.000192	0.00109	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—KRAS—thyroid cancer	0.000187	0.00106	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—KRAS—thyroid cancer	0.000182	0.00103	CbGpPWpGaD
Acamprosate—GRIN1—Neuronal System—HRAS—thyroid cancer	0.000179	0.00101	CbGpPWpGaD
Acamprosate—GABRB3—BDNF signaling pathway—AKT1—thyroid cancer	0.000177	0.001	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—KRAS—thyroid cancer	0.000176	0.000997	CbGpPWpGaD
Acamprosate—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—thyroid cancer	0.000176	0.000995	CbGpPWpGaD
Acamprosate—GRIN2B—Neuronal System—HRAS—thyroid cancer	0.000174	0.000987	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—HRAS—thyroid cancer	0.000159	0.000898	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—NRAS—thyroid cancer	0.000155	0.000876	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—HRAS—thyroid cancer	0.000155	0.000876	CbGpPWpGaD
Acamprosate—GABRB3—Transmission across Chemical Synapses—HRAS—thyroid cancer	0.000154	0.000872	CbGpPWpGaD
Acamprosate—GABRG2—Transmission across Chemical Synapses—HRAS—thyroid cancer	0.000151	0.000856	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—NRAS—thyroid cancer	0.000151	0.000854	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—HRAS—thyroid cancer	0.00015	0.000847	CbGpPWpGaD
Acamprosate—GRM5—GPCR downstream signaling—AKT1—thyroid cancer	0.000145	0.000824	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—CCND1—thyroid cancer	0.00014	0.000794	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—PTEN—thyroid cancer	0.000135	0.000767	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—KRAS—thyroid cancer	0.000133	0.000754	CbGpPWpGaD
Acamprosate—GABRA1—Transmission across Chemical Synapses—HRAS—thyroid cancer	0.000132	0.000748	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—AKT1—thyroid cancer	0.000132	0.000748	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—KRAS—thyroid cancer	0.00013	0.000735	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—NRAS—thyroid cancer	0.000121	0.000684	CbGpPWpGaD
Acamprosate—GABRB3—Neuronal System—HRAS—thyroid cancer	0.000118	0.000668	CbGpPWpGaD
Acamprosate—GABRG2—Neuronal System—HRAS—thyroid cancer	0.000116	0.000656	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—HRAS—thyroid cancer	0.000113	0.000641	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—HRAS—thyroid cancer	0.00011	0.000625	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—KRAS—thyroid cancer	0.000104	0.000589	CbGpPWpGaD
Acamprosate—GABRA1—Neuronal System—HRAS—thyroid cancer	0.000101	0.000573	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—AKT1—thyroid cancer	9.99e-05	0.000566	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—AKT1—thyroid cancer	9.74e-05	0.000552	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—TP53—thyroid cancer	9.24e-05	0.000523	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—HRAS—thyroid cancer	8.83e-05	0.0005	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—AKT1—thyroid cancer	7.8e-05	0.000442	CbGpPWpGaD
